Daejeon, South Korea

Sung Je Moon

This inventor holds 1 USPTO granted patent and 3 published patent applications, plus 1 CIPO patent. Top assignee: Curome Biosciences Co., Ltd.. Active years: 2024.

USPTO Granted Patents = 1 

% Patents Active = 100.0


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Sung Je Moon in Pharmaceutical Composition

Introduction

Sung Je Moon is a notable inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of liver diseases. His innovative work focuses on developing effective compositions that can aid in the prevention and treatment of cholestatic liver disease.

Latest Patents

Sung Je Moon holds 1 patent for his invention titled "Pharmaceutical composition containing B-lapachone as active ingredient for prevention or treatment of cholestatic liver disease." This patent describes a pharmaceutical composition that utilizes β-lapachone as an active ingredient, providing a promising approach to combat cholestatic liver disease effectively.

Career Highlights

Sung Je Moon is associated with Curome Biosciences Co., Ltd., where he continues to advance his research and development efforts. His work is pivotal in the pharmaceutical industry, particularly in creating solutions for complex health issues.

Collaborations

Some of his notable coworkers include Joo Seog Yoon and Kang Sik Seo, who contribute to the collaborative efforts at Curome Biosciences Co., Ltd. Their teamwork enhances the innovative capabilities of the company.

Conclusion

Sung Je Moon's contributions to pharmaceutical innovations, particularly in cholestatic liver disease treatment, highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in medical treatments.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…